All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy, 6 Gy x 5
fractions, to a targetable lesion. Immunotherapy treatment starts with the first radiotherapy
fraction. Nivolumab will be given every 2 weeks. Patients will have specified laboratory
values measured bi-monthly and evaluated for response at 12 weeks as defined by International
Myeloma Working Group Criteria. Patients will continue to receive their respective
immunotherapy until disease progression or dose limiting toxicity is reached.
1. Subject is, in the investigator's opinion, willing and able to comply with the
2. Subject has given voluntary written informed consent before performance of any study
related procedure not part of normal medical care, with the understanding that consent
may be withdrawn by the subject at any time without prejudice to their future medical
3. Must have received 2 consecutive cycles of systemic myeloma therapy.
4. Documented refractory or relapsed and refractory (R/R) multiple myeloma
1. patients had less than minimal response, or had achieved at least a minimal
response to previous treatment, but progressed within 6 months
2. patients must have failed, be intolerant or are ineligible to treatment with an
IMiD, proteasome inhibitor and anti-CD38 agent
5. Targetable plasmacytoma, either intra-or extramedullary that is visualized on imaging
(PET/CT or MRI) and is causing symptoms (eg. pain, neurological compromise) or
potential to cause symptom as per clinician's judgement; and measurable disease at
screening, defined as one or more of the following:
1. Serum IgG, IgA, or IgM M-protein ≥ 0.5 g/dL
2. Urine M-Protein ≥ 200 mg excreted in a 24-hour collection sample
3. Involved serum free light chain (sFLC) > 100 mg/L provided the FLC ratio is
6. Males and Females at least 18 years or legal age of consent per local regulations.
7. Women of childbearing potential (WOCBP) must have two negative serum or urine
pregnancy tests (minimum sensitivity 25 mIU/mL or equivalent units of HCG). One 10-14
days prior to start of the study drug and one within 24 hours prior to the start of
8. Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP
on the importance of pregnancy prevention and the implications of an unexpected
pregnancy Investigators shall advise WOCBP and male subjects who are sexually active
with WOCBP on the use of highly effective methods of contraception. Highly effective
methods of contraception have a failure rate of < 1% when used consistently and
9. No condition which would cause unacceptable risk.
1. Subjects with solitary bone or extramedullary plasmacytoma as the only evidence of
plasm cell dyscrasia.
2. Subjects with monoclonal gammopathy of undetermined significance (MGUS), smoldering
multiple myeloma (SMM), Waldenstrom's macroglobulinemia, or POEMS syndrome (plasma
cell dyscrasia with poly neuropathy, organomegaly, endocrinopathy, monoclonal protein,
and skin changes).
3. Subjects with active plasma cell leukemia (defined as either 20% of peripheral blood
white blood cell count comprised of plasma/CD138+ cells or an absolute plasma cell
count of 2 x 109/L).
4. Subjects within 100 days of stem cell transplantation.
5. Subjects within 4 weeks of surgery, unless cleared by surgeon.
6. Women who are of childbearing potential not complying to the above described
contraceptive measures or are breastfeeding, and sexually active fertile men whose
partners are WOCBP if they are not complying to the above described contraceptive
7. Any uncontrolled or severe cardiovascular or pulmonary disease determined by the
1. NYHA functional classification III or IV, congestive heart failure, unstable or
poorly controlled angina, uncontrolled hypertension, arrhythmia, or myocardial
infarction in the past 12 months
2. Subjects with interstitial lung disease that is symptomatic or may interfere with
the detection or management of suspected drug-related pulmonary toxicity
8. Active infection or know HBV/HCV/HIV.
9. Subjects with an active, known or suspected autoimmune disease. Subjects with type I
diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders
(such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or
conditions not expected to recur in the absence of an external trigger are permitted
10. Subjects with a condition requiring systemic treatment with either corticosteroids (>
10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
days of initiation of study drug. Inhaled or topical steroids, and adrenal replacement
steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of
active autoimmune disease.
11. Previous radiotherapy to the area of the target area.
12. Prior exposure to immunotherapy.